Literature DB >> 19179302

Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function after T cell-depleted allogeneic hematopoietic cell transplantation.

Junli Yu1, Jeffrey M Venstrom, Xiao-Rong Liu, James Pring, Reenat S Hasan, Richard J O'Reilly, Katharine C Hsu.   

Abstract

Alloreactive natural killer (NK) cells are an important influence on hematopoietic stem cell transplantation (HSCT) outcome. In HLA-mismatched HSCT, alloreactivity occurs when licensed donor NK cells expressing inhibitory killer Ig-like receptors (KIR) for donor MHC class I ligands recognize the lack of the class I ligands in the mismatched recipient ("missing self"). Studies in HLA-matched HSCT, however, have also demonstrated improved outcome in patients lacking class I ligands for donor inhibitory KIR ("missing ligand"), indicating that classically nonlicensed donor NK cells expressing KIR for non-self MHC class I ligands may exhibit functional competence in HSCT. We examined NK function in 16 recipients of T cell-depleted allografts from HLA-identical or KIR-ligand matched donors after myeloablative therapy. After HSCT, nonlicensed NK cells expressing inhibitory KIR for non-self class I exhibit robust intracellular IFN-gamma and cytotoxic response to target cells lacking cognate ligand, gradually becoming tolerized to self by day 100. These findings could not be correlated with cytokine environment or phenotypic markers of NK development, nor could they be attributed to non-KIR receptors such as CD94/NKG2A. These findings confirm that NK alloreactivity can occur in HLA-matched HSCT, where tolerance to self is either acquired by the stem cell-derived NK cell after exiting the bone marrow or where tolerance to self can be temporarily overcome.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19179302      PMCID: PMC2670800          DOI: 10.1182/blood-2008-09-177055

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  49 in total

Review 1.  Inhibitory NK-cell receptors on T cells: witness of the past, actors of the future.

Authors:  Eric Vivier; Nicolas Anfossi
Journal:  Nat Rev Immunol       Date:  2004-03       Impact factor: 53.106

2.  The kinetics of circulating cytokines including IL-6, TNF-alpha, IL-8 and IL-10 following allogeneic hematopoietic stem cell transplantation.

Authors:  C K Min; W Y Lee; D J Min; D G Lee; Y J Kim; Y H Park; H J Kim; S Lee; D W Kim; J W Lee; W S Min; C C Kim
Journal:  Bone Marrow Transplant       Date:  2001-11       Impact factor: 5.483

3.  Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors.

Authors:  Sebastian Giebel; Franco Locatelli; Teresa Lamparelli; Andrea Velardi; Stella Davies; Guido Frumento; Rita Maccario; Federico Bonetti; Jerzy Wojnar; Miryam Martinetti; Francesco Frassoni; Giovanna Giorgiani; Andrea Bacigalupo; Jerzy Holowiecki
Journal:  Blood       Date:  2003-04-10       Impact factor: 22.113

4.  Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia.

Authors:  M Hauch; M V Gazzola; T Small; C Bordignon; L Barnett; I Cunningham; H Castro-Malaspinia; R J O'Reilly; C A Keever
Journal:  Blood       Date:  1990-06-01       Impact factor: 22.113

5.  Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.

Authors:  Loredana Ruggeri; Marusca Capanni; Elena Urbani; Katia Perruccio; Warren D Shlomchik; Antonella Tosti; Sabrina Posati; Daniela Rogaia; Francesco Frassoni; Franco Aversa; Massimo F Martelli; Andrea Velardi
Journal:  Science       Date:  2002-03-15       Impact factor: 47.728

6.  Proinflammatory cytokines and their role in the development of major transplant-related complications in the early phase after allogeneic bone marrow transplantation.

Authors:  R Schots; L Kaufman; I Van Riet; T Ben Othman; M De Waele; B Van Camp; C Demanet
Journal:  Leukemia       Date:  2003-06       Impact factor: 11.528

7.  Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation.

Authors:  Heather G Shilling; Karina L McQueen; Nathalie W Cheng; Judith A Shizuru; Robert S Negrin; Peter Parham
Journal:  Blood       Date:  2003-01-02       Impact factor: 22.113

8.  Ex vivo identification, isolation and analysis of tumor-cytolytic T cells.

Authors:  Valerie Rubio; Tor B Stuge; Naileshni Singh; Michael R Betts; Jeffrey S Weber; Mario Roederer; Peter P Lee
Journal:  Nat Med       Date:  2003-10-05       Impact factor: 53.440

9.  Immediate cytotoxicity but not degranulation distinguishes effector and memory subsets of CD8+ T cells.

Authors:  Petra Wolint; Michael R Betts; Richard A Koup; Annette Oxenius
Journal:  J Exp Med       Date:  2004-03-29       Impact factor: 14.307

Review 10.  Biology of natural killer cells.

Authors:  G Trinchieri
Journal:  Adv Immunol       Date:  1989       Impact factor: 3.543

View more
  59 in total

1.  Differential impact of inhibitory and activating Killer Ig-Like Receptors (KIR) on high-risk patients with myeloid and lymphoid malignancies undergoing reduced intensity transplantation from haploidentical related donors.

Authors:  D-F Chen; V K Prasad; G Broadwater; N L Reinsmoen; A DeOliveira; A Clark; K M Sullivan; J P Chute; M E Horwitz; C Gasparetto; G D Long; Y Yang; N J Chao; D A Rizzieri
Journal:  Bone Marrow Transplant       Date:  2011-12-05       Impact factor: 5.483

2.  Mouse Ly49G2+ NK cells dominate early responses during both immune reconstitution and activation independently of MHC.

Authors:  Isabel Barao; Maite Alvarez; Erik Ames; Mark T Orr; Heather E Stefanski; Bruce R Blazar; Lewis L Lanier; Stephen K Anderson; Doug Redelman; William J Murphy
Journal:  Blood       Date:  2011-04-15       Impact factor: 22.113

3.  Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: part II. Autologous Transplantation-novel agents and immunomodulatory strategies.

Authors:  David Avigan; Parameswaran Hari; Minoo Battiwalla; Michael R Bishop; Sergio A Giralt; Nancy M Hardy; Nicolaus Kröger; Alan S Wayne; Katharine C Hsu
Journal:  Biol Blood Marrow Transplant       Date:  2013-09-07       Impact factor: 5.742

Review 4.  Hematopoietic stem cell transplantation for MDS.

Authors:  Matthias Bartenstein; H Joachim Deeg
Journal:  Hematol Oncol Clin North Am       Date:  2010-04       Impact factor: 3.722

Review 5.  Prevention of relapse after allogeneic hematopoietic cell transplantation by donor and cell source selection.

Authors:  Katharina Fleischhauer; Katharine C Hsu; Bronwen E Shaw
Journal:  Bone Marrow Transplant       Date:  2018-05-24       Impact factor: 5.483

Review 6.  Natural Killer Cell Education and the Response to Infection and Cancer Therapy: Stay Tuned.

Authors:  Jeanette E Boudreau; Katharine C Hsu
Journal:  Trends Immunol       Date:  2018-01-31       Impact factor: 16.687

7.  Effect of donor KIR2DL1 allelic polymorphism on the outcome of pediatric allogeneic hematopoietic stem-cell transplantation.

Authors:  Rafijul Bari; Piya Rujkijyanont; Erin Sullivan; Guolian Kang; Victoria Turner; Kwan Gan; Wing Leung
Journal:  J Clin Oncol       Date:  2013-09-16       Impact factor: 44.544

Review 8.  Biology and clinical effects of natural killer cells in allogeneic transplantation.

Authors:  Jonathan E Benjamin; Saar Gill; Robert S Negrin
Journal:  Curr Opin Oncol       Date:  2010-03       Impact factor: 3.645

Review 9.  Natural killer cells: tolerance to self and innate immunity to viral infection and malignancy.

Authors:  Wayne M Yokoyama; Marcus Altfeld; Katharine C Hsu
Journal:  Biol Blood Marrow Transplant       Date:  2009-10-14       Impact factor: 5.742

Review 10.  Immunotherapy of cancer.

Authors:  Hossein Borghaei; Mitchell R Smith; Kerry S Campbell
Journal:  Eur J Pharmacol       Date:  2009-10-20       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.